{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:56:29Z","timestamp":1776934589801,"version":"3.51.2"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["IS-BRC-1215\u201320014"],"award-info":[{"award-number":["IS-BRC-1215\u201320014"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["RG86059"],"award-info":[{"award-number":["RG86059"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.biopha.2022.112808","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T23:12:51Z","timestamp":1647040371000},"page":"112808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["A novel brain-penetrant oral UGT8 inhibitor decreases in vivo galactosphingolipid biosynthesis in murine Krabbe disease"],"prefix":"10.1016","volume":"149","author":[{"given":"Eva","family":"Zaccariotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Bego\u00f1a","family":"Cach\u00f3n-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungtaek","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford","family":"Hirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyejung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malika","family":"Fezoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.Pablo","family":"Sardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Robert H.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112808_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/brain\/39.1-2.74","article-title":"New familial, infantile form of diffuse brain-sclerosis","volume":"39","author":"Krabbe","year":"1916","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2022.112808_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1073\/pnas.66.2.302","article-title":"Globoid cell leukodystrophy (Krabbe\u2019s disease): de\ufb01ciency of galactocerebroside \u03b2-galactosidase","volume":"66","author":"Suzuki","year":"1970","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.112808_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2183\/pjab.79B.1","article-title":"Evolving perspective of the pathogenesis of globoid cell leukodystrophy (Krabbe disease)","volume":"79","author":"Suzuki","year":"2003","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.biopha.2022.112808_bib4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/08830738030180090201","article-title":"Globoid cell leukodystrophy (Krabbe\u2019s disease): update","volume":"18","author":"Suzuki","year":"2003","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.biopha.2022.112808_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-2275(20)39839-4","article-title":"Krabbe disease: a galactosylsphingosine (psychosine) lipidosis","volume":"21","author":"Svennerholm","year":"1980","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.biopha.2022.112808_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.6719111","article-title":"Progressive accumulation of toxic metabolite in a genetic leukodystrophy","volume":"224","author":"Igisu","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112808_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00005072-196504000-00008","article-title":"Studies in globoid (Krabbe) Leukodystrophy. 3. Significance of experimentally-produced globoid-like elements in rat white matter and spleen","volume":"24","author":"Austin","year":"1965","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"4","key":"10.1016\/j.biopha.2022.112808_bib8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1083\/jcb.149.4.943","article-title":"Inhibition of cytokinesis by a lipid metabolite, psychosine","volume":"149","author":"Kanazawa","year":"2000","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2022.112808_bib9","first-page":"5398","article-title":"Galactosylsphingosine galactosyl hydrolase","volume":"247","author":"Miyatake","year":"1972","journal-title":"Partial Purif. Prop. Enzym. Rat. Brain J. Biol. Chem."},{"issue":"40","key":"10.1016\/j.biopha.2022.112808_bib10","doi-asserted-by":"crossref","first-page":"20097","DOI":"10.1073\/pnas.1912108116","article-title":"Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target","volume":"116","author":"Li","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.biopha.2022.112808_bib11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10545-012-9560-4","article-title":"Krabbe disease in adults: phenotypic and genotypic update from a series of 11 cases and a review","volume":"36","author":"Debs","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.biopha.2022.112808_bib12","series-title":"GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle","first-page":"1993","article-title":"Krabbe disease","author":"Orsini","year":"2000"},{"key":"10.1016\/j.biopha.2022.112808_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pediatrneurol.2012.02.023","article-title":"Later onset phenotypes of Krabbe disease: results of the world-wide registry","volume":"46","author":"Duffner","year":"2012","journal-title":"Pedia Neurol."},{"issue":"10","key":"10.1016\/j.biopha.2022.112808_bib14","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41436-019-0480-7","article-title":"Clinical characteristics of 248 patients with Krabbe disease: quantitative natural history modeling based on published cases","volume":"21","author":"Komatsuzaki","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.biopha.2022.112808_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jnnp.26.3.195","article-title":"Diagnosis of Krabbe\u2019s infantile leukodystrophy","volume":"26","author":"Hagberg","year":"1963","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.biopha.2022.112808_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S0317167100016188","article-title":"Phenotypic variability of Krabbe disease across the lifespan","volume":"41","author":"Liao","year":"2014","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.biopha.2022.112808_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/brain\/103.3.695","article-title":"Hereditary leucodystrophy in the mouse: The new mutant Twitcher","volume":"103","author":"Duchen","year":"1980","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2022.112808_bib18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0006-8993(80)90159-6","article-title":"The Twitcher mouse: An enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease)","volume":"202","author":"Kobayashi","year":"1980","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2022.112808_bib19","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1471-4159.1996.66031118.x","article-title":"Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease","volume":"66","author":"Sakai","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2022.112808_bib20","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1093\/hmg\/ddt190","article-title":"Missense mutation in mouse GALC mimics human gene defect and offers new insights into Krabbe disease","volume":"22","author":"Potter","year":"2013","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.biopha.2022.112808_bib21","first-page":"165","article-title":"Globoid cell leukodystrophy (Krabbe type) in the dog","volume":"149","author":"Fletcher","year":"1966","journal-title":"J. Am. Vet. Med Assoc."},{"key":"10.1016\/j.biopha.2022.112808_bib22","first-page":"375","article-title":"Animal model: globoid cell leukodystrophy in the dog","volume":"66","author":"Fletcher","year":"1972","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2022.112808_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/geno.1996.0220","article-title":"Cloning of the canine GALC cDNA and identi\ufb01cation of the mutation causing globoid cell leukodystrophy in West Highland white and Cairn terriers","volume":"33","author":"Victoria","year":"1996","journal-title":"Genomics"},{"key":"10.1016\/j.biopha.2022.112808_bib24","first-page":"138","article-title":"Globoid cell leukodystrophy in Cairn and West Highland white terriers","volume":"90","author":"Wenger","year":"1999","journal-title":"Am. Genet. Assoc."},{"key":"10.1016\/j.biopha.2022.112808_bib25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/030098588001700402","article-title":"Globoid cell leukodystrophy in polled Dorset sheep","volume":"17","author":"Pritchard","year":"1980","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.biopha.2022.112808_bib26","first-page":"60","article-title":"Galactosylceramide-lipidosis in rhesus monkeys","author":"Baskin","year":"1989","journal-title":"Lab Invest"},{"key":"10.1016\/j.biopha.2022.112808_bib27","first-page":"476","article-title":"Genetic galactocerebrosidase de\ufb01ciency (globoid cell leukodystrophy, Krabbe\u2019s disease) in rhesus monkeys (Macaca mulatta)","volume":"48","author":"Baskin","year":"1998","journal-title":"Lab Anim. Sci."},{"key":"10.1016\/j.biopha.2022.112808_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/mgme.2001.3194","article-title":"Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leukodystrophy (Krabbe disease)","volume":"73","author":"Luzi","year":"2001","journal-title":"Molec Genet Metab."},{"key":"10.1016\/j.biopha.2022.112808_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.expneurol.2015.04.020","article-title":"Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy","volume":"271","author":"Matthes","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2022.112808_bib30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.bbadis.2014.01.008","article-title":"Molecular cloning and knockdown of galactocerebrosidase in zebra\ufb01sh: new insights into the pathogenesis of Krabbe\u2019s disease","author":"Zizioli","year":"2014","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.biopha.2022.112808_bib31","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJM199804163381605","article-title":"Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy","volume":"338","author":"Krivit","year":"1998","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2022.112808_bib32","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of umbilical-cord blood in babies with infantile Krabbe\u2019s disease","volume":"352","author":"Escolar","year":"2005","journal-title":"N. Engl. J. Med"},{"issue":"13","key":"10.1016\/j.biopha.2022.112808_bib33","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood.2020005477","article-title":"Long-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease","volume":"137","author":"Yoon","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.biopha.2022.112808_bib34","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/jnr.23822","article-title":"Treatment for Krabbe disease: Finding the combination","volume":"94","author":"Mikulka","year":"2016","journal-title":"J. Neurosci. Res"},{"key":"10.1016\/j.biopha.2022.112808_bib35","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/jnr.23752","article-title":"Perspective on innovative therapies for globoid cell leukodystrophy","volume":"94","author":"Ricca","year":"2016","journal-title":"J. Neurosci. Res"},{"issue":"2","key":"10.1016\/j.biopha.2022.112808_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.beem.2015.01.001","article-title":"Innovative treatments for lysosomal diseases","volume":"29","author":"Cox","year":"2015","journal-title":"Best. Pr. Res Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2022.112808_bib37","first-page":"637","article-title":"A possible therapeutic approach to Krabbe\u2019s globoid leukodystrophy and the status of cerebroside synthesis in the disorder","volume":"3","author":"Radin","year":"1972","journal-title":"Res Commun. Chem. Pathol. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2022.112808_bib38","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1194\/jlr.E039131","article-title":"In memoriam: Norman S. Radin (1920-2013)","volume":"54","author":"Shayman","year":"2013","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/j.biopha.2022.112808_bib39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"issue":"12","key":"10.1016\/j.biopha.2022.112808_bib40","doi-asserted-by":"crossref","first-page":"F996","DOI":"10.1152\/ajprenal.00393.2015","article-title":"Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective","volume":"309","author":"Shayman","year":"2015","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"20","key":"10.1016\/j.biopha.2022.112808_bib41","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1021\/acschemneuro.0c00558","article-title":"Optimization of eliglustat-based glucosylceramide synthase inhibitors as substrate reduction therapy for gaucher disease type 3","volume":"11","author":"Wilson","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2022.112808_bib42","first-page":"S144","article-title":"Venglustat combined with imiglucerase positively affects neurological features and brain connectivity in adults with Gaucher disease type 3","volume":"129","author":"Schiffmann","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2022.112808_bib43","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/bi00830a008","article-title":"Synthesis of cerebroside by brain from uridine diphosphate galactose and ceramide containing hydroxy fatty acid","volume":"8","author":"Morell","year":"1969","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.biopha.2022.112808_bib44","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/jnr.23761","article-title":"Zoledronate derivatives as potential inhibitors of uridine diphosphate-galactose ceramide galactosyltransferase 8: A combined molecular docking and dynamic study","volume":"94","author":"Pannuzzo","year":"2016","journal-title":"J. Neurosci. Res"},{"key":"10.1016\/j.biopha.2022.112808_bib45","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1471-4159.1984.tb02716.x","article-title":"Inhibition of sphingolipid synthesis by cycloserine in vitro and in vivo","volume":"42","author":"Sundaram","year":"1984","journal-title":"J. Neurochem"},{"key":"10.1016\/j.biopha.2022.112808_bib46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1097-4547(20000415)60:2<231::AID-JNR12>3.0.CO;2-E","article-title":"L-cycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice)","volume":"60","author":"LeVine","year":"2000","journal-title":"J. Neurosci. Res"},{"key":"10.1016\/j.biopha.2022.112808_bib47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1203\/00006450-200201000-00009","article-title":"Substrate-reduction therapy enhances the bene\ufb01ts of bone marrow transplantation in young mice with globoid cell leukodystrophy","volume":"51","author":"Biswas","year":"2002","journal-title":"Pedia Res"},{"key":"10.1016\/j.biopha.2022.112808_bib48","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1523\/JNEUROSCI.4199-14.2015","article-title":"Mechanism-based combination treatment dramatically increases therapeutic ef\ufb01cacy in murine globoid cell leukodystrophy","volume":"35","author":"Hawkins-Salsbury","year":"2015","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.biopha.2022.112808_bib49","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0028-3908(86)90236-4","article-title":"L-cycloserine: behavioural and biochemical effects after single and repeated administration to mice, rats and cats","volume":"25","author":"Polc","year":"1986","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.biopha.2022.112808_bib50","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0006-2952(00)00251-3","article-title":"Specificity of inhibitors of serine palmitoyltransferase (SPT), a key enzyme in sphingolipid biosynthesis, in intact cells. A novel evaluation system using an SPT-defective mammalian cell mutant","volume":"59","author":"Hanada","year":"2000","journal-title":"Biochem Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2022.112808_bib51","doi-asserted-by":"crossref","first-page":"14486","DOI":"10.1038\/s41598-021-93601-1","article-title":"Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor","volume":"11","author":"Babcock","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2022.112808_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/EBC20190090","article-title":"Lyso-glycosphingolipids: presence and consequences","volume":"64","author":"van Eijk","year":"2020","journal-title":"Essays Biochem"},{"issue":"10","key":"10.1016\/j.biopha.2022.112808_bib53","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1021\/acsmedchemlett.0c00120","article-title":"Brain penetrable inhibitors of ceramide galactosyltransferase for the treatment of lysosomal storage disorders","volume":"11","author":"Thurairatnam","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2022.112808_bib54","first-page":"24","article-title":"US Patent 11,098,056 B2, Genzyme Corporation, Cambridge MA","author":"Lim","year":"2021","journal-title":"Awarded"},{"issue":"8","key":"10.1016\/j.biopha.2022.112808_bib55","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/mt.2012.44","article-title":"Gene transfer corrects acute GM2 gangliosidosis--potential therapeutic contribution of perivascular enzyme flow","volume":"20","author":"Cach\u00f3n-Gonz\u00e1lez","year":"2012","journal-title":"Mol. Ther."},{"issue":"22","key":"10.1016\/j.biopha.2022.112808_bib56","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/hmg\/ddab159","article-title":"Expression of RipK1 and DAM genes correlates with severity and progression of Krabbe disease","volume":"30","author":"Cach\u00f3n-Gonz\u00e1lez","year":"2021","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.biopha.2022.112808_bib57","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.35.8.1505566","article-title":"Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease","volume":"35","author":"Shayman","year":"2010","journal-title":"Drugs Future"},{"key":"10.1016\/j.biopha.2022.112808_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bcmd.2018.04.001","article-title":"Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1","volume":"71","author":"Mistry","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"issue":"1\u20133","key":"10.1016\/j.biopha.2022.112808_bib59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0009-3084(86)90047-2","article-title":"Phylogenetic development of myelin glycosphingolipids","volume":"42","author":"Kishimoto","year":"1986","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.biopha.2022.112808_bib60","first-page":"323","article-title":"Neural functions of glycolipids","volume":"volume 4","author":"Schnaar","year":"2007"},{"key":"10.1016\/j.biopha.2022.112808_bib61","first-page":"290","article-title":"Oligodendrocyte development and myelin biogenesis: parsing out the roles of glycosphingolipids","volume":"24","author":"Jackman","year":"2009","journal-title":"Physiol. (Bethesda)"},{"issue":"2","key":"10.1016\/j.biopha.2022.112808_bib62","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1152\/physrev.00058.2017","article-title":"The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms","volume":"99","author":"Meech","year":"2019","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2022.112808_bib63","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00018-003-3003-1","article-title":"How sphingolipids bind and shape proteins: molecular basis of lipid-protein interactions in lipid shells, rafts and related biomembrane domains","volume":"60","author":"Fantini","year":"2003","journal-title":"Cell Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.biopha.2022.112808_bib64","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/(SICI)1097-4547(20000115)59:2<170::AID-JNR3>3.0.CO;2-G","article-title":"Biochemistry and neuropathology of mice doubly deficient in synthesis and degradation of galactosylceramide","volume":"59","author":"Ezoe","year":"2000","journal-title":"J. Neurosci. Res"},{"issue":"2","key":"10.1016\/j.biopha.2022.112808_bib65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/(SICI)1097-4547(20000115)59:2<179::AID-JNR4>3.0.CO;2-N","article-title":"Twitcher mice with only a single active galactosylceramide synthase gene exhibit clearly detectable but therapeutically minor phenotypic improvements","volume":"59","author":"Ezoe","year":"2000","journal-title":"J. Neurosci. Res"},{"issue":"3","key":"10.1016\/j.biopha.2022.112808_bib66","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/0006-291X(82)91987-8","article-title":"An accumulation of galactocerebroside in kidney from mouse globoid cell leukodystrophy (twitcher)","volume":"109","author":"Ida","year":"1982","journal-title":"Biochem Biophys. Res Commun."},{"issue":"3","key":"10.1016\/j.biopha.2022.112808_bib67","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/0006-291X(83)91053-7","article-title":"Abnormal accumulation of galactosylceramide in the kidney of twitcher mouse","volume":"110","author":"Igisu","year":"1983","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2022.112808_bib68","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0022-2275(20)33431-3","article-title":"Kidney lipids in galactosylceramide synthase-de\ufb01cient mice. Absence of galactosylsulfatide and compensatory increase in more polar sulfoglycolipids","volume":"41","author":"Tadano-Aritomi","year":"2000","journal-title":"J. Lipid Res"},{"issue":"2","key":"10.1016\/j.biopha.2022.112808_bib69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0092-8674(00)80093-8","article-title":"Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability","volume":"86","author":"Coetzee","year":"1996","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2022.112808_bib70","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1471-4159.2005.03221.x","article-title":"Reversal of non-hydroxy:alpha-hydroxy galactosylceramide ratio and unstable myelin in transgenic mice overexpressing UDP-galactose:ceramide galactosyltransferase","volume":"94","author":"Fewou","year":"2005","journal-title":"J. Neurochem"},{"issue":"1","key":"10.1016\/j.biopha.2022.112808_bib71","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1194\/jlr.M700400-JLR200","article-title":"FA2H is responsible for the formation of 2-hydroxy galactolipids in peripheral nervous system myelin","volume":"49","author":"Maldonado","year":"2008","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.biopha.2022.112808_bib72","doi-asserted-by":"crossref","first-page":"13280","DOI":"10.1073\/pnas.93.23.13280","article-title":"Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis","volume":"93","author":"Bosio","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.biopha.2022.112808_bib73","first-page":"691","article-title":"Enhanced Efficacy and Increased Long-Term Toxicity of CNS-Directed","volume":"29","author":"Li","year":"2021","journal-title":"AAV-Based Comb. Ther. Krabbe Dis. Mol. Ther."},{"issue":"16","key":"10.1016\/j.biopha.2022.112808_bib74","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1074\/jbc.RA119.012502","article-title":"Glucocerebrosidases catalyze a transgalactosylation reaction that yields a newly-identified brain sterol metabolite, galactosylated cholesterol","volume":"295","author":"Akiyama","year":"2020","journal-title":"J. Biol. Chem."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222001962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222001962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:27:31Z","timestamp":1774250851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222001962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":74,"alternative-id":["S0753332222001962"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112808","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel brain-penetrant oral UGT8 inhibitor decreases in vivo galactosphingolipid biosynthesis in murine Krabbe disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112808"}}